SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-263369
Filing Date
2022-10-17
Accepted
2022-10-17 07:40:32
Documents
14
Period of Report
2022-10-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d393962d8k.htm   iXBRL 8-K 33209
2 EX-99.1 d393962dex991.htm EX-99.1 20705
6 GRAPHIC g393962g1017074206594.jpg GRAPHIC 3813
  Complete submission text file 0001193125-22-263369.txt   187611

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ngm-20221017.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20221017_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20221017_pre.xml EX-101.PRE 10811
8 EXTRACTED XBRL INSTANCE DOCUMENT d393962d8k_htm.xml XML 3296
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 221312568
SIC: 2834 Pharmaceutical Preparations